Alpha-GPC
Italian multicenter trials (De Jesus Moreno, 2003) in Alzheimer's patients found Alpha-GPC improved memory scores more than placebo over 90 days. Sports studies (Bellar et al., 2015) confirm power output increases in athletes at 600mg. Of all choline sources, Alpha-GPC has the strongest acute cognitive data.
Mechanism of action
Alpha-GPC (alpha-glycerylphosphorylcholine) is the most bioavailable choline precursor. It delivers choline directly across the blood-brain barrier, where it is used to synthesise acetylcholine. It also stimulates growth hormone secretion and supports cell membrane phospholipid synthesis.
Clinical evidence summary
Italian multicenter trials (De Jesus Moreno, 2003) in Alzheimer's patients found Alpha-GPC improved memory scores more than placebo over 90 days. Sports studies (Bellar et al., 2015) confirm power output increases in athletes at 600mg. Of all choline sources, Alpha-GPC has the strongest acute cognitive data.
Human effect matrix
Based on human clinical trials only. Animal and in-vitro data excluded.
| Effect | Evidence | Magnitude | Studies |
|---|---|---|---|
| Acetylcholine Synthesis | strong | Large | 9 |
| Memory Encoding | strong | Moderate | 7 |
| Athletic Power Output | moderate | Moderate | 3 |
| Neuroprotection | moderate | Moderate | 4 |
Evidence key: Strong = multiple consistent RCTs · Moderate = smaller/fewer RCTs · Preliminary = early trials or small n · Mixed = conflicting results
Documented benefits
- Acetylcholine synthesis
- Memory encoding
- Athletic power output
- Neuroprotection
Side effects & cautions
- Well tolerated
- Headache if combined with other cholinergics
- Potential cardiovascular concern at very high doses (>1200mg/day)
How to take
Stacking recommendations
Ingredients that pair well with Alpha-GPC and why.
Alpha-GPC provides immediate acetylcholine support; Lion's Mane drives long-term NGF synthesis. Neither overlaps mechanistically — a clean acute + long-term pairing.
Alpha-GPC handles acute memory encoding via acetylcholine; Bacopa handles memory consolidation and storage. Together they cover both encoding and consolidation stages of memory formation.
Huperzine A prevents acetylcholine breakdown while Alpha-GPC increases acetylcholine synthesis. Powerful combination in theory — but use with caution and low doses, as cholinergic overload (nausea, headache, muscle cramps) is a real risk. Not recommended without experience.
Frequently asked questions
Alpha-GPC vs Citicoline — which is better for focus?
Both are excellent. Alpha-GPC has a slight edge for acute cholinergic effects and is preferred for workout performance. Citicoline also provides cytidine (uridine precursor), giving it a broader neuroprotective profile. For pure focus and acetylcholine, Alpha-GPC wins slightly; for comprehensive brain health support, Citicoline is more complete. Don't stack them together — you'll get too much choline activity.
Is it safe to combine Alpha-GPC with Huperzine A?
Use caution. Both increase acetylcholine (Alpha-GPC via synthesis, Huperzine A via inhibiting breakdown). The combination is potent and can cause cholinergic overstimulation — symptoms include nausea, headache, excessive salivation, and muscle cramps. If combining, use lower doses of each (e.g. 200mg Alpha-GPC + 50mcg Huperzine A) and do not take daily.
Why does Alpha-GPC powder go sticky?
Alpha-GPC is highly hygroscopic — it absorbs water from the air quickly. This is normal and doesn't affect potency. Store in an airtight container in a cool, dry place. Capsule form avoids this problem entirely.
Is there a cardiovascular risk with Alpha-GPC?
A 2021 observational study suggested a possible association between high Alpha-GPC intake (>1200mg/day) and cardiovascular events via TMAO production. This was in older adults at very high doses. At standard supplementation doses (300–600mg/day) in healthy individuals, no cardiovascular signal has been found in controlled trials. The benefit/risk profile at standard doses is positive.
Top stacks containing Alpha-GPC
Alpha-GPC in the EU
Alpha-GPC is moving through the EU's novel food process. An application covering L-alpha-GPC derived from soya phospholipids has a public dossier summary published by the European Commission in its ongoing-applications series (file 2023-12770), and EFSA published a favourable safety opinion in 2026 finding no safety concerns under the proposed conditions of use. A scientific safety opinion is a separate step from the Commission's formal authorisation, which is what adds a novel food to the Union list and determines whether and how it may be placed on the EU market.
Safety Opinion Issued, Authorisation Still Pending
EFSA's 2026 opinion on L-alpha-GPC from soya phospholipids as a novel food concluded favourably on safety, stating "the Panel concludes that the NF does not raise safety concerns under the proposed conditions of use." This opinion responds to a novel food application submitted under Regulation (EU) 2015/2283, and the Commission's public dossier summary for that application is filed under ongoing applications. Under Article 6(2) of the Regulation, "only novel foods authorised and included in the Union list may be placed on the market," so the Commission's authorisation step, not the EFSA opinion, is what governs sale.
Products in the EU
EU food supplement (Reg. 1924/2006 claims)
Is alpha-GPC officially approved as a novel food ingredient in the EU?
The EU treats these as separate steps. EFSA has issued a favourable safety opinion, and the Commission's published dossier summary for the L-alpha-GPC application sits in its ongoing-applications series. Market authorisation requires a Commission act adding the ingredient to the Union list of authorised novel foods; check the current Union list for the up-to-date status.
Did EFSA find safety concerns with alpha-GPC?
No. EFSA's 2026 scientific opinion concluded that the novel food "does not raise safety concerns under the proposed conditions of use." A favourable safety opinion is a necessary step toward authorisation, but it is not itself the market authorisation.
EU country guides
Sources: EFSA Journal 2026;24(5):e10008 — Safety of L-alpha-glycerylphosphorylcholine (L-alpha-GPC) from soya phospholipids as a novel food · European Commission public summary of the ongoing novel food dossier for L-alpha-GPC from soya phospholipids (lecithin) · Regulation (EU) 2015/2283, Article 6(2) -- only authorised novel foods may be marketed
Regulatory note
Cognitive-effect language on this page describes ingredient mechanisms studied in clinical trials. Health claims on supplements sold in the EU are governed by Regulation (EC) No 1924/2006; only European Food Safety Authority (EFSA) approved claims may appear on product labelling. This page is editorial, not promotional, and does not constitute medical advice. Consult a qualified healthcare professional before starting any supplement.